Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Nov 23;22(1):357.
doi: 10.1186/s12871-022-01897-x.

Combined use of intranasal Dexmedetomidine and an oral novel formulation of Midazolam for sedation of young children during brain MRI examination: a prospective, single-center, randomized controlled trial

Hongbin Gu #  1   2 , Liyan Miao #  2   3 , Jie Bai  1   2 , Guolin Lu  2   3 , Qian Lei  2 , Lijun Yang #  4   5 , Denggui Wang #  6   7
Affiliations
Randomized Controlled Trial

Combined use of intranasal Dexmedetomidine and an oral novel formulation of Midazolam for sedation of young children during brain MRI examination: a prospective, single-center, randomized controlled trial

Hongbin Gu et al. BMC Anesthesiol. .

Abstract

Background: To evaluate the safety and effectiveness of different dosages of intranasal Dexmedetomidine (DEX) in combination with oral midazolam for sedation of young children during brain MRI examination.

Methods: Included in this prospective single-blind randomized controlled trial were 156 children aged from 3 months to 6 years and weighing from 4 to 20 Kg with ASA I-II who underwent brain MRI examination between March 2021 and February 2022. Using the random number table method, they were divided into group A (using 3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam) and group B (using 2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam). The one-time success rate of sedation, sedation onset time, recovery time, overall sedation time, and occurrence of adverse reactions during MRI examination were compared between the two groups. The heart rate (HR), mean arterial pressure (MAP), and percutaneous SpO2before and after drug administration were observed in both groups. Differences in sedation scores between the two groups were compared before intranasal drug administration (T0), 10 min after drug administration (T1), at the time of falling asleep (T2), at the end of examination (T3), and at the time of recovery (T4).

Results: The one-time success rate of sedation in group A and B was 88.31% and 79.75% respectively, showing no significant difference between the two groups (P>0.05). The sedation onset time in group A was 24.97±16.94 min versus 27.92±15.83 min in group B, and the recovery time was 61.88±22.18 min versus 61.16±28.16 min, both showing no significance difference between the two groups (P>0.05). Children in both groups exhibited good drug tolerance without presenting nausea and vomiting, hypoxia, or bradycardia and hypotension that needed clinical interventions. There was no significant difference in the occurrence of abnormal HR, MAP or other adverse reactions between the two groups (P>0.05).

Conclusion: 3 ug/kg or 2 ug/kg intranasal DEX in combination with 0.2 mg/kg oral Midazolam both are safe and effective for sedation of children undergoing MRI examination with the advantages of fast-acting and easy application.

Trial registration: It was registered at the Chinese Clinical Trial Registry ( ChiCTR1800015038 ) on 02/03/2018.

Keywords: Brain MRI; Dexmedetomidine; Midazolam; Oral; Pediatrics; Sedation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig 1
Fig 1
Flow chart of the experiment
See this image and copyright information in PMC

References

    1. Karasu D, et al. The frequency of emergence delirium in children undergoing outpatient anaesthesia for magnetic resonance imaging. Int J Clin Pract. 2021;75(11):e14763. doi: 10.1111/ijcp.14763. - DOI - PubMed
    1. van Hoorn CE, et al. Off-label use of dexmedetomidine in paediatric anaesthesiology: an international survey of 791 (paediatric) anaesthesiologists. Eur J Clin Pharmacol. 2021;77(4):625–635. doi: 10.1007/s00228-020-03028-2. - DOI - PMC - PubMed
    1. Tervonen M, et al. Systematic review and meta-analysis found that intranasal dexmedetomidine was a safe and effective sedative drug during paediatric procedural sedation. Acta Paediatr. 2020;109(10):2008–2016. doi: 10.1111/apa.15348. - DOI - PubMed
    1. Zadrazil M, et al. ADV6209 for Premedication in Pediatric Anesthesia: A Double-Blinded, Randomized Controlled Trial. Pharmaceutics. 2022;14(10):2062. doi: 10.3390/pharmaceutics14102062. - DOI - PMC - PubMed
    1. Salman S, et al. A novel, palatable paediatric oral formulation of midazolam: pharmacokinetics, tolerability, efficacy and safety. Anaesthesia. 2018;73(12):1469–1477. doi: 10.1111/anae.14318. - DOI - PubMed

Publication types

LinkOut - more resources